ImmunityBioIBRX
Recorded

ImmunityBio UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Dejia ZhangAnalyst

My name is Dejia Zhang, and I am part of the UBS coverage team. We are very excited to host this first inaugural biotech conference here in London. I am also really excited to introduce Richard Adcock as CEO of ImmunityBio.

Richard AdcockCEO

Thank you. Thank you. I would love to just say, first of all, thank you to the UBS team for inviting us to speak here, and for those in the room, but also for those listening online. Everybody is familiar with forward-looking statements on these pieces. On these, I would refer you to our website for any of these pieces if you have questions. When you think about ImmunityBio and Dr. Patrick Soon-Shiong, who is the founder and really the scientific and medical visionary that has brought all of this together, the way of thinking about ImmunityBio is, first and foremost, is that we have a number of different platforms, our fusion proteins, our DNA vaccine vectors, and our cell therapies.

Richard AdcockCEO

While people talk a lot about, and today we will talk a lot about ANKTIVA, I always remind people that we are not just a one-drug and one-indication company, and that is what separates us from many of the other companies that are out there. If you look at our fusion proteins, you will see, which is really ANKTIVA, and I always like to say it is the first product that is approved inside of there. There is an entire pipeline of other fusion proteins that we are working through from very early stages through on that as well. ANKTIVA, and we will talk about that most of the day, is now approved in 35 different countries across multiple indications. I am going to spend most of the time today really talking about ANKTIVA, or as here, our IL-15.

Richard AdcockCEO

When Dr. Soon-Shiong first brought this out, what he said is, "My belief and our belief is that ANKTIVA can become the backbone across all immunotherapy, whether it is ours or somebody else's." Our job, obviously, that is not done. We are under trials with many of those, but it is really to prove that out. I think we are under a very strong basis of that with the approvals that we have in bladder cancer, now an expanded label in bladder cancer, as well as lung cancer in Saudi Arabia and the United Arab Emirates. Obviously, more work to do there. If you look at it, IL-15 is a backbone compared to checkpoints like Keytruda.

Richard AdcockCEO

You'll see whereas Keytruda, and I'm not trying to do a head-to-head here, has got 19 different tumor types that they set this out, and there's so far nothing we've seen that doesn't give us belief that we can have effectiveness in many of these as well. But in lymphopenia, which we know, and if you look at the approved FDA label, what it says is that it activates and proliferates CD8 killer T cells, helper T cells, memory T cells without Treg. That's what lymphocytes are, is your natural killer cells and T cells. Right inside of the FDA label, and we've had this conversation with them, is we believe they've already approved the first lymphocyte-stimulating agent on those. Now, our job is to bring that from bladder cancer across all of the other ones.

Richard AdcockCEO

But the market opportunity is quite remarkable because one in five adults suffer from this, 54 million people on those. So these are just astronomically large indications through those. The one that we're really excited about, and we've been working with this with ANKTIVA, is now in sepsis. A phase II trial has now been fully authorized. We're working with sites like Cleveland Clinic and others around the country and world to be able to set that up. Two reasons that I'll say we're really excited about sepsis is, first, no one's been able to touch it. Our early work we've done in single-patient INDs we've done have shown the exact effect we're looking for, because if you look at sepsis, what happens, you've got this hyperinflammation phase, and then they crash. What's crashing? The lymphocytes. By there you go. Then you know specifically. From a hospital, and I ran large health systems, and part of my background, ran large health insurance companies as well, sepsis is one of the most expensive treatments because nothing does.

Richard AdcockCEO

If, unfortunately, many people die, and if they don't, it can be a very long drawn-out event from those. So sepsis is one. Well, early, the teams that we've been working with, and again, Cleveland Clinic, when we presented this to them, they're like, "This is one of the most exciting things we've seen because it impacts on all sides of this." Then our cancer vaccine, what we've been doing with the NIH on that for Lynch syndrome, one in 279 or 1.2 million Americans.

Richard AdcockCEO

All of these talk about just what is the potential size of a just very large market, but it demonstrates what is the opportunity for ANKTIVA to act, as Dr. Soon-Shiong originally said, the backbone across all immunotherapy. Now, I'm not going to go through every one of these. I like to say this. I was just in a one-on-one investor meeting, and the thing he told me was he said, "You guys just keep delivering one after the other one." I told him, I said, "Everything that we've said we're going to do, we're going to do. We keep checking them off.

Richard AdcockCEO

The one variable that we can't always control is time, but if we don't get the time we want, we just keep after it and keep working through those." I just addressed our team, and I'll just share this as a little side story back at ImmunityBio because we got the expanded label for papillary or full BCG-unresponsive. What I told the team there was I said, "The thing I'm most proud about all of you is resilience, because whenever you get something that stops in front of you, we don't stop. We just keep working our way through it." If you look at this now going through these franchises in bladder cancer, all of these, BCG-unresponsive, unresponsive with papillary, they really come together to now just be a BCG-unresponsive product.

Richard AdcockCEO

Our BCG-naïve, this one we'll be talking more about this as well, and then BCG alternative options from those. Lung cancer, again, moving on those lymphopenia, and then as we talked about, our cancer vaccine. Let's go now into BCG-unresponsive space. Right out of our package insert, if you look at those, the European label is 53 months and ongoing duration. That's what makes ANKTIVA so special, and you'll probably hear about it in one of the videos coming up here, is that memory T-cell really separates it. Yes, you get a response. Yes, you need the natural killer cells, you need the T-cells, but you need that long-term duration. This is what separates ANKTIVA from everybody else, and it's duration, duration.

Richard AdcockCEO

Some of the key highlights on those, 84% of the patients who responded to ANKTIVA were able to maintain their bladders at 36 months. That's right out of the New England Journal of Medicine papers and The Journal of Urology papers. 71% of the participants had a complete response, meaning their complete cancer was eliminated from those 53 months of duration, as I indicated. That's right out of our European label on those 99% disease-specific overall survival at three months. These are the types of things that set this up as truly what we believe, and the labels are demonstrating it, is a best in class. We've had great success so far with our commercial launch, from payers being on board and launching in all of these different countries now. Commercial sales continue to expand on all of those different pieces.

Richard AdcockCEO

Our BCG-unresponsive, again, through all of this quarter we had was the smaller label, CIS plus and minus papillary. Now we've just received in the last couple of weeks even the label expansion on that. Here is just another look at this and trying to take a look at it in units you'll see on those. That's our BCG-unresponsive space. I'll share this story with you, is we got our approval, and there was many people who didn't think we were going to get it. I had sincerely over probably the two or three days afterwards, 20-plus doctors call me and say, "Congratulations." Almost all of them said the same thing, "Finally, we can now just get back to treating patients the way we used to." Because we didn't used to have this nomenclature of CIS plus and minus and papillary only and all of this.

Richard AdcockCEO

They were just BCG-unresponsive patients. They were high-risk patients. ANKTIVA is the only one that has full FDA labels to be able to treat that BCG-unresponsive patient like that, and we believe that will separate you as well again. In the naïve space, this is very important because we've finished and we've submitted this out there, our BCG-naïve trial. The independent data monitoring safety committee has met and said, "You don't have to continue to expand that trial." We just reported out in the last days that we had met the endpoint to our BCG-naïve trial, and we'll be talking more about that in the middle. As you can see, this is a very large indication as well, giving us much more on those.

Richard AdcockCEO

Getting that first approval, then the label expansion, and now submitting and moving forward to that in the naïve setting even continues the story more. In BCG, our ANKTIVA plus BCG in the naïve setting, we've demonstrated this with the earliest phase I patients. They're now out 9+ years. There was originally nine patients inside of theirs when we were getting our unresponsive first indication label. The FDA called and said, "We'd like to know where those patients are." We had to smile and say, "You mean the patients that we were authorized to track for two years? You'd like to know where they're at 8+ years later?" They smiled and said, "Yeah, and if you could do it by Tuesday, that'd be great." Somewhat not joking. Fortunately, they were all at one center. We called that center right away. They were fantastic. They said, "We'll open an IRB for you tonight.

Richard AdcockCEO

You guys can come. We'll give you all access to all of the data." We were able to identify six of six. Two had passed of diseases other than bladder cancer. One was unidentifiable because no one was supposed to be tracking. But six of six patients, all 6 of those were still in complete response nine and a half years later. All of them had not had another treatment, and most importantly, all of them still had their bladders intact. That is really remarkable, and that's the power of the duration that we're really excited about on those. The conclusion on that one is ANKTIVA plus BCG in those patients is a durable complete response. It's not just a complete response, but a durable complete response.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day